Flirting with Fraud: Why Sextortion Is the Most Devastating Dating Scam
Sextortion has emerged as one of the most dangerous forms of romance scams, preying on online daters and, tragically, claiming the lives of teenagers. Fraudsters use fake profiles to lure victims into sharing intimate content, only to threaten exposure unless a ransom is paid. Regula, a global developer of identity verification (IDV) solutions, shares a vision of how social media and dating platforms can strengthen protections to safeguard users.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250213790016/en/

Can you spot a romance scam? Scammers are getting smarter, using fake identities, AI, and emotional manipulation to exploit trust. See how these scams work and what can be done to stop them. (Graphic: Regula)
Romance scams come in many forms, exploiting trust and emotional vulnerability to defraud victims. Their common tactics include:
- Catfishing: Scammers create fake identities to build trust and manipulate victims.
- Military Scams: Fraudsters pose as deployed soldiers seeking financial assistance.
- Inheritance Scams: Victims are deceived with false claims of large inheritances requiring upfront fees.
- Pig-Butchering (Crypto Investment) Scams: Scammers feign romantic interest to lure victims into fraudulent investment schemes.
However, according to reports from leading child safety organizations, including the National Center for Missing and Exploited Children (NCMEC) and Thorn, sextortion is one of the most severe threats, with cases surging at an alarming rate. The FBI reported over 12,000 complaints in 2023 alone, resulting in millions in financial losses, severe psychological trauma, and, in some cases, even fatalities. Younger users and those new to online dating are particularly vulnerable.
Common sextortion tactics include:
- Fake Identities: Scammers pose as attractive singles, influencers, or even celebrities to build quick trust.
- Rapid Escalation: Conversations quickly shift from introductions to intimate exchanges.
- Blackmail Threats: Once explicit content is shared, scammers demand money, cryptocurrency, or further compromising images under the threat of exposure.
- AI-Driven Deception: Some scams leverage deepfake videos or AI-powered chatbots to manipulate victims.
The Role of Identity Verification in Preventing Sextortion
Sextortion thrives in environments where fake profiles and anonymity enable bad actors to operate freely. Social media and dating platforms play a critical role in combating this threat—through proactive moderation, AI-powered content monitoring, and user education. Stronger identity verification during registration is also a valuable tool in this arsenal, but it must be implemented thoughtfully, balancing fraud prevention with user privacy and accessibility.
Different online platforms use varying levels of verification, ranging from strongest to weakest:
- ID & Biometric Verification – Matching government-issued IDs with real-time selfies for authentication.
- Real-Time Selfies Without ID Validation – Confirming a live presence but without a verified identity document.
- Basic Checks – Verification through phone numbers, email, or linked social media accounts.
- Self-Reported Identity Without Validation – The least secure method, relying solely on user-provided information.
How Biometric and ID Verification Strengthens Security:
- Eliminating Fake Profiles: Biometric checks make it significantly harder for scammers to create fake accounts.
- Anti-Spoofing Technology: Prevents impersonation by detecting fraudulent attempts using photos or masks.
- Liveness Detection: Confirms a real person is present, preventing AI-generated deception.
“When faced with strong verification measures, scammers don’t simply disappear—they move to less secure platforms where they can continue their schemes unchecked. Standardizing biometric ID verification across multiple platforms would make it significantly harder for them to do so, creating a safer ecosystem across social media, dating apps, and other online services." – Jan Stepnov, Identity Verification Expert at Regula.
Empowering Users to Stay Safe
While platforms must take stronger security measures, users can also protect themselves by:
- Being Cautious of Fast-Moving Relationships: Avoid engaging in intimate exchanges early in conversations.
- Interacting with Verified Users: Prioritize connections with verified profiles.
- Reporting Suspicious Activity: Flagging blackmail attempts and scam behavior.
- Never Paying Ransoms: Complying with extortion often leads to further threats.
For more insights on how identity verification is transforming online dating security, visit Regula’s blog.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213790016/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom